Cranomax | UTI Prevention | D-Mannose + Cranberry

Dual-Pathway UTI Prevention

Antibiotics treat UTIs but can't prevent them. Cranomax targets the root cause — bacterial adhesion to the urinary tract wall — through two independent anti-adhesion mechanisms, giving comprehensive protection against recurrent uncomplicated UTIs.

🛡️ Anti-Adhesion, Not Antibiotic

D-Mannose competitively inhibits Type 1 fimbrial adhesion while Cranberry PAC-A prevents P-fimbriated bacteria from sticking. Together they block both major adhesion pathways — bacteria can't cause infection if they can't attach.

Request Product Information

How Cranomax Works: Two Independent Defenses

Most UTI supplements rely on just one mechanism. Cranomax blocks bacteria at two distinct attachment points simultaneously.

🔵

Pathway 1: D-Mannose

E. coli uses Type 1 fimbriae with FimH lectins to grip mannose receptors on urinary tract cells. D-Mannose floods the urine, saturating FimH — bacteria grip mannose in the urine instead of the bladder wall, and are flushed out on urination.

🍒

Pathway 2: PAC-A (Cranberry)

Type A proanthocyanidins from cranberry prevent P-fimbriated E. coli (a distinct adhesion pathway) from attaching to uroepithelial cells. Together with D-Mannose, this creates a complete dual anti-adhesion shield.

The Science Behind Each Ingredient

🔬

D-Mannose (600mg)

Rapidly absorbed and excreted unchanged in urine. Twice-daily dosing delivers 1.2g/day — exceeding the 1g/day clinically studied preventive dose. Achieves effective urinary concentrations for FimH competitive inhibition.

🍒

Cranberry Extract (450mg)

Standardized to 25% proanthocyanidins — delivering 112.5mg total PACs. ~30-35% are Type A PACs, providing ~36mg PAC-A per sachet: the clinically established anti-adhesion dose for recurrent UTI prevention.

🌺

Hibiscus Extract (250mg)

Standardized to 20% polyphenols — delivering 50mg bioactive compounds. Clinical evidence supports 250-500mg/day for antimicrobial and anti-biofilm activity. Adjunct bacterial growth inhibition while maintaining tolerability.

Complete Urinary Health Formula

Each ingredient in Cranomax is clinically dosed and serves a distinct, evidence-based role in urinary tract protection and comfort.

D-M

D-Mannose >99% Purity (600mg/sachet)

1.2g/day with twice-daily dosing. Exceeds minimum clinically studied dose. Rapidly absorbed, excreted unchanged in urine. Competitive FimH inhibitor — no antibiotic resistance risk.

PAC

Cranberry Extract 25% PAC (450mg)

Standardized by UV Method. Provides ~36mg Type A PACs — the clinically established dose. Prevents P-fimbriated E. coli adhesion independent of D-Mannose. Dual-pathway synergy.

HE

Hibiscus Extract 20% Polyphenols (250mg)

Standardized by GV Method. Delivers 50mg bioactive compounds. Demonstrated antimicrobial and anti-biofilm activity in clinical studies. Adjunct to anti-adhesion protection.

KMC

Potassium Magnesium Citrate (978mg)

~2g/day with twice-daily dosing — aligning with established urinary alkalization regimens. Modulates urinary pH, improves citrate levels, relieves dysuria, and maintains electrolyte safety.

Clinical Dosing — Every Sachet

D-Mannose (per sachet) 600mg ✓

Minimum clinical dose: 500mg/sachet (2×/day)

Type A PACs (Cranberry) ~36mg ✓

Clinically established anti-adhesion dose: 36mg PAC-A

Hibiscus Polyphenols 50mg ✓

Clinical range: 40-100mg polyphenols/day

Potassium Mg Citrate (2×/day) ~2g ✓

Established alkalization regimen: ~2g/day

Every ingredient dosed to clinical evidence — not just label claims

Cranomax vs Typical UTI Supplements

Feature	Cranomax	Standard Cranberry Capsule	Basic D-Mannose
Adhesion Pathways Blocked	✓ Both (Type 1 + P-fimbrial)	P-fimbrial only	Type 1 only
D-Mannose Dose	600mg (clinical)	None	Varies
PAC Standardization	✓ 25% PAC (UV Method)	Often unstandardized	None
PAC-A Content	~36mg (clinical dose)	Unknown	None
Hibiscus Anti-biofilm	✓ 250mg standardized	None	None
Urinary pH Support	✓ K-Mg Citrate (978mg)	None	None
Dysuria Relief	✓ Yes (alkalization)	✗ No	✗ No
Antibiotic Resistance Risk	✓ None (non-antibiotic)	✓ None	✓ None

Who Benefits from Cranomax?

🔄

Recurrent UTI Sufferers

3+ UTIs per year? Cranomax's dual anti-adhesion mechanism interrupts the recurrence cycle without contributing to antibiotic resistance.

🤰

Pregnancy

UTIs are more common and dangerous in pregnancy. D-Mannose and cranberry PAC-A provide safe, non-antibiotic preventive support throughout pregnancy.

👩

Post-Menopausal Women

Declining estrogen alters urinary tract microbiome and increases UTI risk. Cranomax provides non-hormonal preventive protection.

💊

Antibiotic-Sparing Strategy

Patients and clinicians seeking to reduce antibiotic dependency. Cranomax works by blocking adhesion — no bacterial kill, no resistance development.

🏥

Post-Catheterization

Catheter-related UTIs are a major clinical concern. D-Mannose provides preventive urinary tract protection in at-risk patients.

🔥

Dysuria & Discomfort

Potassium Magnesium Citrate alkalizes urine and relieves the burning sensation during urination — providing symptomatic relief alongside prevention.

The Cranomax Difference

2x

Defense Pathways

Type 1 + P-fimbrial blocked simultaneously

36mg

PAC-A Per Sachet

The clinically established anti-adhesion dose

0

Antibiotic Resistance

Non-antibiotic — bacteria can't adapt

4-in-1

Active Ingredients

Each clinically dosed per evidence